Fresenius Capital Surpluse vs Accounts Payable Analysis

FMS Stock

USD 22.02 0.46 2.05%

Fresenius Medical financial indicator trend analysis is much more than just examining Fresenius Medical Care latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fresenius Medical Care is a good investment. Please check the relationship between Fresenius Medical Capital Surpluse and its Accounts Payable accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Capital Surpluse vs Accounts Payable

Capital Surpluse vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fresenius Medical Care Capital Surpluse account and Accounts Payable. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Fresenius Medical's Capital Surpluse and Accounts Payable is -0.51. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Fresenius Medical Care, assuming nothing else is changed. The correlation between historical values of Fresenius Medical's Capital Surpluse and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Fresenius Medical Care are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Capital Surpluse i.e., Fresenius Medical's Capital Surpluse and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.51

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Capital Surpluse

Accounts Payable

An accounting item on the balance sheet that represents Fresenius Medical obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Fresenius Medical Care are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Fresenius Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fresenius Medical Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At this time, Fresenius Medical's Tax Provision is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 9.38 in 2024, whereas Selling General Administrative is likely to drop slightly above 3 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	5.1B	5.3B	4.9B	3.7B
Total Revenue	17.6B	19.4B	19.5B	11.4B

Gross Profit Total Revenue

Fresenius Medical fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Common Stock Shares Outstanding		-0.56	-0.65	-0.67	-0.54	-0.49	-0.58	-0.66	-0.55	-0.32	-0.37	-0.61	-0.67	-0.41	-0.09	0.18	-0.59	-0.68	-0.47	-0.59	-0.6	-0.55	-0.36	-0.5	0.0	-0.11
Total Assets	-0.56		0.97	0.69	0.94	0.98	0.62	0.94	0.87	0.95	0.67	1.0	0.63	0.73	0.85	0.56	0.94	0.82	0.13	0.86	0.99	0.4	0.96	0.77	-0.34	0.51
Short Long Term Debt Total	-0.65	0.97		0.65	0.89	0.91	0.63	0.99	0.81	0.87	0.55	0.98	0.67	0.61	0.77	0.45	0.97	0.78	0.14	0.84	0.99	0.38	0.87	0.75	-0.26	0.42
Other Current Liab	-0.67	0.69	0.65		0.79	0.7	0.7	0.6	0.81	0.56	0.82	0.69	0.59	0.82	0.39	0.15	0.53	0.87	0.6	0.82	0.66	0.64	0.64	0.75	0.04	0.05
Total Current Liabilities	-0.54	0.94	0.89	0.79		0.96	0.63	0.84	0.84	0.9	0.77	0.94	0.6	0.8	0.79	0.45	0.8	0.79	0.13	0.92	0.92	0.36	0.92	0.92	-0.21	0.37
Total Stockholder Equity	-0.49	0.98	0.91	0.7	0.96		0.59	0.86	0.86	0.96	0.75	0.97	0.59	0.8	0.86	0.56	0.88	0.81	0.09	0.88	0.95	0.35	0.97	0.8	-0.37	0.53
Property Plant And Equipment Net	-0.58	0.62	0.63	0.7	0.63	0.59		0.62	0.8	0.56	0.61	0.63	0.14	0.66	0.49	0.43	0.57	0.79	0.5	0.6	0.62	0.86	0.57	0.61	-0.2	0.33
Net Debt	-0.66	0.94	0.99	0.6	0.84	0.86	0.62		0.77	0.83	0.45	0.96	0.67	0.53	0.73	0.44	0.97	0.75	0.14	0.8	0.97	0.37	0.82	0.69	-0.23	0.4
Retained Earnings	-0.55	0.87	0.81	0.81	0.84	0.86	0.8	0.77		0.85	0.81	0.86	0.56	0.88	0.75	0.6	0.79	0.97	0.38	0.78	0.85	0.68	0.85	0.66	-0.35	0.5
Accounts Payable	-0.32	0.95	0.87	0.56	0.9	0.96	0.56	0.83	0.85		0.66	0.93	0.48	0.73	0.95	0.72	0.87	0.75	-0.02	0.79	0.92	0.33	0.97	0.7	-0.45	0.62
Cash	-0.37	0.67	0.55	0.82	0.77	0.75	0.61	0.45	0.81	0.66		0.64	0.4	0.99	0.55	0.33	0.45	0.78	0.31	0.72	0.6	0.52	0.74	0.7	-0.31	0.35
Non Current Assets Total	-0.61	1.0	0.98	0.69	0.94	0.97	0.63	0.96	0.86	0.93	0.64		0.66	0.71	0.82	0.51	0.95	0.82	0.13	0.87	1.0	0.4	0.93	0.77	-0.32	0.5
Non Currrent Assets Other	-0.67	0.63	0.67	0.59	0.6	0.59	0.14	0.67	0.56	0.48	0.4	0.66		0.44	0.3	-0.06	0.65	0.62	0.17	0.66	0.66	0.08	0.49	0.45	-0.06	0.11
Cash And Short Term Investments	-0.41	0.73	0.61	0.82	0.8	0.8	0.66	0.53	0.88	0.73	0.99	0.71	0.44		0.62	0.43	0.54	0.84	0.31	0.74	0.67	0.55	0.79	0.7	-0.35	0.43
Net Receivables	-0.09	0.85	0.77	0.39	0.79	0.86	0.49	0.73	0.75	0.95	0.55	0.82	0.3	0.62		0.84	0.79	0.6	-0.16	0.65	0.83	0.22	0.91	0.6	-0.47	0.63
Common Stock Total Equity	0.18	0.56	0.45	0.15	0.45	0.56	0.43	0.44	0.6	0.72	0.33	0.51	-0.06	0.43	0.84		0.55	0.45	0.01	0.25	0.54	0.32	0.69	0.23	-0.35	0.54
Non Current Liabilities Total	-0.59	0.94	0.97	0.53	0.8	0.88	0.57	0.97	0.79	0.87	0.45	0.95	0.65	0.54	0.79	0.55		0.76	0.11	0.73	0.97	0.38	0.86	0.58	-0.35	0.53
Inventory	-0.68	0.82	0.78	0.87	0.79	0.81	0.79	0.75	0.97	0.75	0.78	0.82	0.62	0.84	0.6	0.45	0.76		0.53	0.79	0.81	0.72	0.78	0.62	-0.25	0.39
Other Current Assets	-0.47	0.13	0.14	0.6	0.13	0.09	0.5	0.14	0.38	-0.02	0.31	0.13	0.17	0.31	-0.16	0.01	0.11	0.53		0.15	0.12	0.74	0.11	0.1	0.44	-0.36
Other Stockholder Equity	-0.59	0.86	0.84	0.82	0.92	0.88	0.6	0.8	0.78	0.79	0.72	0.87	0.66	0.74	0.65	0.25	0.73	0.79	0.15		0.84	0.31	0.78	0.88	-0.17	0.27
Total Liab	-0.6	0.99	0.99	0.66	0.92	0.95	0.62	0.97	0.85	0.92	0.6	1.0	0.66	0.67	0.83	0.54	0.97	0.81	0.12	0.84		0.39	0.93	0.74	-0.32	0.49
Property Plant And Equipment Gross	-0.55	0.4	0.38	0.64	0.36	0.35	0.86	0.37	0.68	0.33	0.52	0.4	0.08	0.55	0.22	0.32	0.38	0.72	0.74	0.31	0.39		0.38	0.26	-0.11	0.22
Total Current Assets	-0.36	0.96	0.87	0.64	0.92	0.97	0.57	0.82	0.85	0.97	0.74	0.93	0.49	0.79	0.91	0.69	0.86	0.78	0.11	0.78	0.93	0.38		0.72	-0.36	0.54
Short Term Debt	-0.5	0.77	0.75	0.75	0.92	0.8	0.61	0.69	0.66	0.7	0.7	0.77	0.45	0.7	0.6	0.23	0.58	0.62	0.1	0.88	0.74	0.26	0.72		-0.02	0.14
Intangible Assets	0.0	-0.34	-0.26	0.04	-0.21	-0.37	-0.2	-0.23	-0.35	-0.45	-0.31	-0.32	-0.06	-0.35	-0.47	-0.35	-0.35	-0.25	0.44	-0.17	-0.32	-0.11	-0.36	-0.02		-0.94
Common Stock	-0.11	0.51	0.42	0.05	0.37	0.53	0.33	0.4	0.5	0.62	0.35	0.5	0.11	0.43	0.63	0.54	0.53	0.39	-0.36	0.27	0.49	0.22	0.54	0.14	-0.94

Click cells to compare fundamentals

Fresenius Medical Account Relationship Matchups

Fresenius Medical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	302.7M	294.3M	293.1M	293.2M	293.4M	405.8M
Total Assets	32.9B	31.7B	34.4B	35.8B	33.9B	18.7B
Short Long Term Debt Total	13.8B	12.4B	13.3B	13.2B	12.1B	6.2B
Other Current Liab	2.7B	3.0B	3.6B	3.3B	3.4B	3.5B
Total Current Liabilities	7.0B	6.2B	7.3B	6.5B	6.1B	3.6B
Total Stockholder Equity	13.2B	12.3B	14.0B	15.4B	13.6B	7.8B
Property Plant And Equipment Net	8.5B	4.1B	4.3B	4.2B	7.5B	7.8B
Net Debt	12.8B	11.3B	11.8B	11.9B	10.6B	5.7B
Retained Earnings	9.5B	10.3B	10.8B	10.7B	10.9B	11.5B
Accounts Payable	835.2M	827.4M	818.5M	892.6M	839.1M	545.6M
Cash	1.0B	1.1B	1.5B	1.3B	1.4B	1.5B
Non Current Assets Total	25.8B	24.4B	26.4B	27.6B	25.2B	13.8B
Non Currrent Assets Other	752.5M	4.8B	5.2B	5.0B	681.8M	1.0B
Cash And Short Term Investments	1.1B	1.2B	1.6B	1.4B	1.5B	1.6B
Net Receivables	4.0B	3.6B	3.6B	3.7B	3.6B	2.6B
Common Stock Total Equity	308.1M	307.9M	304.4M	292.9M	336.8M	304.7M
Liabilities And Stockholders Equity	32.9B	31.7B	34.4B	35.8B	33.9B	18.7B
Non Current Liabilities Total	12.7B	13.2B	13.1B	13.8B	13.0B	7.2B
Inventory	1.7B	1.9B	2.0B	2.3B	2.2B	2.3B
Other Current Assets	320.7M	455.7M	730.8M	725.8M	1.3B	1.4B
Other Stockholder Equity	4.5B	4.0B	4.2B	4.8B	3.4B	3.2B
Total Liab	19.7B	19.4B	20.4B	20.3B	19.1B	10.8B
Property Plant And Equipment Gross	8.5B	8.2B	4.3B	4.2B	17.9B	17.0B
Total Current Assets	7.2B	7.3B	8.0B	8.2B	8.7B	4.9B
Accumulated Other Comprehensive Income	(1.0B)	(2.2B)	(1.3B)	(388.5M)	(975.2M)	(926.4M)
Short Term Debt	3.3B	1.7B	2.6B	2.0B	1.6B	1.1B
Intangible Assets	1.4B	1.4B	1.5B	1.5B	1.4B	1.7B
Common Stock	304.4M	292.9M	293.0M	293.4M	337.4M	258.6M
Current Deferred Revenue	201.0M	606.3M	518.0M	105.7M	26.9M	25.5M
Other Liab	2.1B	2.5B	2.4B	2.7B	3.1B	3.2B
Other Assets	1.1B	1.1B	1.2B	1.1B	1.3B	1.4B
Long Term Debt	6.5B	6.8B	6.6B	7.2B	7.0B	5.7B
Property Plant Equipment	8.5B	8.2B	8.6B	8.3B	9.6B	10.1B
Good Will	14.0B	13.0B	14.4B	15.8B	14.7B	13.9B
Short Term Investments	133.3M	161.7M	136.4M	170.0M	136.3M	140.2M
Net Tangible Assets	(3.5B)	(3.1B)	(3.1B)	(3.3B)	(3.8B)	(4.0B)
Long Term Investments	696.9M	761.1M	786.9M	773.7M	1.3B	853.1M
Short Long Term Debt	2.6B	1.1B	1.9B	1.4B	944.6M	1.7B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Fresenius Stock Analysis

When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC